Compare XTNT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | RVPH |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6M | 71.0M |
| IPO Year | N/A | N/A |
| Metric | XTNT | RVPH |
|---|---|---|
| Price | $0.83 | $0.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $3.33 |
| AVG Volume (30 Days) | 231.4K | ★ 4.7M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $133,083,000.00 | N/A |
| Revenue This Year | $15.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $68.87 | ★ N/A |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $0.34 | $0.25 |
| 52 Week High | $0.95 | $2.17 |
| Indicator | XTNT | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.71 | 48.77 |
| Support Level | $0.70 | $0.48 |
| Resistance Level | $0.81 | $0.67 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.42 | 36.51 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.